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Abstract. The PI3K-AKT-mTOR signaling axis is central to 
the transformed phenotype of glioblastoma (GBM) cells, due 
to frequent loss of tumor suppressor PTEN (phosphatase and 
tensin homolog deleted on chromosome 10). The mechanistic 
target of rapamycin (mTOR) kinase is present in two cellular 
multi-protein complexes, mTORC1 and mTORC2, which have 
distinct subunit composition, substrates and mechanisms of 
action. Targeting the mTOR protein is a promising strategy 
for GBM therapy. However, neither of these complexes is fully 
inhibited by the allosteric inhibitor of mTOR, rapamycin or 
its analogs. Herein, we provide evidence that the combined 
inhibition of mTORC1/2, using the ATP-competitive binding 
inhibitor PP242, would effectively suppress GBM growth and 
dissemination as compared to an allosteric binding inhibitor 
of mTOR. GBM cells treated with PP242 demonstrated 
significantly decreased activation of mTORC1 and mTORC2, 
as shown by reduced phosphorylation of their substrate 
levels, p70 S6KThr389 and AKTSer473, respectively, in a dose-
dependent manner. Furthermore, insulin induced activation 
of these kinases was abrogated by pretreatment with PP242 
as compared with rapamycin. Unlike rapamycin, PP242 
modestly activates extracellular regulated kinase (ERK1/2), 
as shown by expression of pERKThr202/Tyr204. Cell proliferation 
and S-phase entry of GBM cells was significantly suppressed 
by PP242, which was more pronounced compared to 
rapamycin treatment. Lastly, PP242 significantly suppressed 
the migration of GBM cells, which was associated with a 
change in cellular behavior rather than cytoskeleton loss. In 
conclusion, these results underscore the potential therapeutic 
use of the PP242, a novel ATP-competitive binding inhibitor 
of mTORC1/2 kinase, in suppression of GBM growth and 
dissemination. 
Introduction
Glioblastoma (GBM; WHO defined grade IV astrocytoma) 
is the most prevalent and uniformly lethal primary brain 
tumor (1). Conventional treatment modalities including 
maximum surgical resection, radiotherapy and chemotherapy 
extend median survival time of approximately 14 months 
after diagnosis (1). Subsequent use of temozolomide (TMZ or 
Temodar) offers GBM patients additional survival time with 
an acceptable quality of life. In recent years, efforts have been 
made to use more targeted or immune-therapies. Despite all 
of these attempts, GBM remains an incurable disease. Genetic 
and molecular dichotomy, along with specific clinical course 
of disease and age of onset of disease, defines GBM into two 
broad categories, primary GBM, which develops de novo 
or secondary GBM, which progresses from a low-grade or 
anaplastic astrocytoma (2). Recent investigations have strati-
fied GBMs into 4 subclasses, namely classical, proneural, and 
mesenchymal based on the levels of expression and activity 
of core proteins of signal transduction pathways such as 
epidermal growth factor receptor (EGFR), PDGF, and NF1, 
respectively, and neural (2). 
Furthermore, these genetic classifications are shown to 
be better prognostic indicators of disease than defined histo-
logical criteria. Detailed genetic analyses have defined three 
signaling pathways, namely RTK/RAS/PI3K, P53 and RB, as 
critical for the development of GBM. Mutations of the tumor 
suppressor, PTEN, which occur at an estimated frequency 
of 70-90%, are involved in gliomagenesis by modulating the 
function of its associated downstream proteins (3-6). The 
tumor suppressive function of PTEN is shown to be impaired 
after subtle expression downregulation, even in the presence 
of a wild-type gene copy, a process recognized as functionally 
haploinsufficient (7), which contributes to tumor formation (8). 
Biochemically, PTEN dephosphorylates the lipid second 
messenger phosphatidylinositol 3,4,5-trisphosphate to 
generate phosphatidylinositol 3,4-bisphosphate, which func-
tions antagonistically to the PI3K. Consequently, the PTEN 
tumor suppressor is a central negative regulator of the PI3K/
PDK1/AKT signaling axis that controls multiple cellular 
functions including cell growth, survival, proliferation, and 
angio genesis (9), and loss of PTEN leads to a constitutive 
activation of oncogenic pathways. In addition, a lack of PTEN 
expression leads to an increase in the pool of self-renewing 
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neural stem cells and induces loss of homeostatic control of 
proliferation, thereby indicating cell cycle dysregulation during 
gliomagenesis (10). Moreover, in the absence of PTEN, there is 
an upregulation of the phosphoinositide 3-kinase (PI3K)/AKT 
pathway involved in regulation of cellular processes such 
as transcription, translation, cell cycle progression and 
apoptosis (4,11). AKT (protein kinase B), a serine/threonine 
protein kinase, regulates cell growth and survival by activating 
multiple downstream targets, including GSK-3B, p21, p27 and 
NF-κB and activation of AKT plays a crucial role in glioma-
genesis as shown in animal models (11,12).
Mechanistic target of rapamycin (mTOR) functions 
through the canonical PI3K/AKT pathway, which is deregu-
lated in many cancers including GBM (13-15). mTOR is a 
serine-threonine kinase which functions via two multi-protein 
complexes, namely mTORC1 and mTORC2, each character-
ized by different binding partners and confer distinct functions. 
mTORC1 integrates signals from growth factor receptors 
with cellular nutritional status, and regulates the level of cap-
dependent mRNA translation by altering the activity of key 
translational components such as the cap-binding protein and 
oncogene eIF4E (16). The mTORC1 complex is composed 
of proteins such as regulatory associated protein of mTOR 
(RAPTOR), which is sensitive to rapamycin treatment. It has 
been shown that mTORC1 function is tightly regulated by 
PI3K/AKT.
In contrast to mTORC1, the mTORC2 complex is sensi-
tive to growth factors but not nutrients, and is associated with 
the rapamycin-insensitive companion of mTOR (RICTOR) 
along with other proteins (15). The major distinguishing char-
acteristic of the mTORC1 and mTORC2 is their differential 
sensitivity to rapamycin (17-20). mTORC1 regulates protein 
synthesis through phosphorylating its downstream substrates, 
4EBP1 (also called EIF4EBP1) and p70 S6K1/2 (21,22). The 
mTOR-dependent phosphorylation of p70 S6K1/2 promotes 
translation initiation as well as elongation and regulates 
cellular growth (23). mTORC2 modulates growth factor 
signaling by phosphorylating the C-terminal hydrophobic 
motif of some AGC kinases, such as AKT and SGK (24,25). 
Activated mTORC2 activation leads to phosphorylation of 
AKTSer473 (26). Pharmacological inhibition of these complexes 
has been difficult to achieve. a phase I trial of rapamycin in 
PTen-deficient GBM patients showed some promising results, 
although faced some inherent difficulties of targeting mTOR 
pathway, as a significant number of patients showed increased 
activated levels of pAKTSer473 following rapamycin treatment, 
which was correlated with shorter time to progression (27). 
The observed AKT activation was likely due to an alteration 
of signaling feedback loops, again highlighting the complexity 
of prolonged rapamycin treatment (28).
Growth factor stimulation of PI3K causes activation of 
AKT by the phosphorylation of two key amino acid resi-
dues, namely the activation loop at T308 and the C-terminal 
hydrophobic motif at S473. Activated AKT promotes cell 
survival, proliferation and suppresses apoptosis. The disrup-
tion of mTORC2 by different genetic and pharmacological 
approaches has variable effects on AKT phosphorylation. For 
example, targeting mTORC2 by RNA interference (RNAi), 
homologous recombination, or long-term rapamycin treatment 
results in loss of AKT hydrophobic motif phosphorylation 
(S473), strongly implicating mTORC2 as the kinase responsible 
for phosphorylation of this site (29-32).
Rapamycin (sirolimus) and its analogs, such as RAD001 
(everolimus) and CCI-779 (temsirolimus), suppress mTOR 
activity through an allosteric mechanism that acts at a distance 
from the ATP-binding catalytic site. Major disadvantages of 
rapamycin, and other related compounds, are that it suppresses 
TORC1 mediated S6K activation, thereby blocking a negative 
feedback loop, leading to activation of PI3K/AKT and Ras/
MEK/ERK signaling pathways thus promoting cell survival 
and growth. In recent years, novel small ATP binding site 
molecules have been identified that directly inhibit mTOR, 
unlike rapamycin, which is an allosteric inhibitor of mTOR. 
In addition, novel ATP-competitive binding compounds with 
pyrazolopyrimidines are shown to inhibit members of the 
PI3K family, including mTOR. One such compound, PP242, is 
an ATP-competitive inhibitor of mTOR, which shows potent 
and selective inhibition of mTORC1 and mTORC2 (33). These 
molecules are often termed ‘TORKinibs’ for their ability to 
inhibit TOR kinase. In this study, we compared PP242 with 
rapamycin and demonstrate that PP242 effectively inhibits 
mTORC1 and mTORC2 and suppresses GBM cell prolifera-
tion and migration.
Materials and methods
Cell lines. The GBM cell line Ln-18 (aTCC, Manassas, Va, 
USA) was used to investigate the effect of combined mTORC1/2 
inhibitor to assess its effectiveness as compared to the mTORC1 
inhibitor rapamycin. LN-18 cell line has an underlying p53 
mutation at codon 238 where TGT (Cys) --> TCT (Ser) and 
wild-type PTEN.
Cell culture. Cells were maintained in DMEM (Invitrogen, 
Carlsbad, CA, USA) supplemented with 10% FBS and 1% 
penicillin/streptomycin/amphotericin in a humidified 5% 
CO2 incubator at 37˚C. Cells were made quiescent by serum 
deprivation 24 h prior to treatment with various combina-
tions of rapamycin (RAPA, mTOR inhibitor, 100 nM) (EMD 
Chemicals, Billerica, MA, USA), Phorbol 12-myristate 
13-acetate, PMA, TPA (10 nM) (Sigma-Aldrich, St. Louis, 
MO, USA), PP242 (1 or 2.2 µM) (EMD Chemicals), Insulin 
(10 µM) (Sigma-Aldrich), fibronectin (FN, extra-cellular 
matrix, 20 ng/ml) (Sigma-Aldrich).
Isolation of protein. Quiescent cells were subjected to following 
treatments: PP242 (1.1 or 2.2 µM) or rapamycin (100 nM) for 
24 h, or Insulin (10 µM) or TPA (10 nM) for 30 min. In addi-
tion, cells were pretreated with rapamycin or PP242 (24 h) 
followed by treatment with insulin or TPa for 30 min. Vehicle 
treated cells were considered as controls. Protein extraction 
was done using whole cell lysis buffer containing 1% Triton 
X-100, 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA 
with phosphatase and protease inhibitors (Sigma-Aldrich). 
Protein concentrations were determined by the modified 
Lowry Method (Bio-Rad Laboratory, Hercules, CA, USA).
Western blot analysis. An equal amount of protein (50 µg) 
was resolved on a 10% SDS-PAGE gel and then electro-
transferred onto nitrocellulose membrane. Membranes were 
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processed according to the manufacturers' instructions (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA; Cell Signaling 
Technology, Danvers, MA, USA) using primary antibodies 
for phosphorylated and total AKT, ERK, p70 S6K and 
GAPDH bands were detected by chemiluminescence (Cell 
Signaling Technology). Blots were stripped with reagent 
(EMD Chemicals) and re-probed with actin or respective total 
antibodies to ensure equal loading. All reported bands were 
analyzed using ImageJ (NIH, Bethesda, MD, USA) and plotted 
against total protein values. Experiments were conducted at 
least 3 times.
Chemotactic migration. Directional migration was performed 
using a 48-well modified Boyden chamber kit (neuroProbe, 
Gaithersburg, MD, USA). Quiescent cells were treated with 
rapamycin (10 nM) or PP242 (2.2 µM) for 24 h. Vehicle 
treated cells served as controls. Cells were aliquoted 
(3,000 cells/µl) in either serum free media or their respective 
treated media. Fibronectin (20 ng/ml) (Sigma-Aldrich) was 
used as a chemoattractant and cells were allowed to migrate 
for 4 h through a PVC membrane (8 µm pore). The membrane 
was fixed in 70% ethanol, scraped along the non-migrated cell 
surface, and stained with DiffQuick (IMEB, San Marcos, CA, 
USA). Migrated cells were imaged at 2.5X (Axiovert 100 M) 
and analyzed as a percentage of total microscopic field occu-
pied by migrated cells using ImageJ (NIH).
Cell viability. Cell viability was measured by MTT assay 
according to the manufacturer's protocol (Chemicon, Billerica, 
MA, USA). Cells (approximately 3,000/well) were seeded onto 
a 96-well plate and made quiescent for 24 h prior to treatment. 
Rapamycin (100 nM) or PP242 (1 or 2.2 µM) was given to 
cells in serum-free media for 24 h. After completion of treat-
ment, fresh media (90 µl) with MTT (10 µl) reagent/well was 
added and plates were incubated at 37˚C for 4 h. The reac-
tion was stopped by adding DMSO and absorbance (595 and 
630 nM) was measured using Multiskan™ FC Microplate 
Reader (Fisher Scientific, Waltham, Ma, uSa).
EdU incorporation for S-phase entry analysis. Cell cycle 
analysis was visualized by utilizing the Click-iT EdU Imaging 
kit (Invitrogen, Grand Island, NY, USA). Quiescent cells were 
treated with vehicle, rapamycin, PP242 or PDGF for 4 h and 
then incubated with 5-ethynyl-2-deoxyuridine (EdU: 10 µM) 
for 4 h. Cells were subsequently fixed in 4% paraformaldehyde 
for 15 min at room temperature and permeabilized for 15 min 
in 0.1% Triton X-100 in PBS. EdU incorporation was detected 
by incubation with Alexa 488-Click-iT reaction cocktail at 
room temperature for 30 min. Nascent protein synthesis was 
estimated by determining the signal intensity of Alexa 488. 
Frequency maps of the cell proliferation were constructed 
from fluorescence images using a Zeiss microscope and 
analyzed by ImageJ (NIH). The number of Alexa 488-labeled 
cells was recorded against the DaPI labeled cells to define 
cells entering into S-phase.
Results
The ATP-competitive binding inhibitor PP242 inhibits both 
mTORC1 and mTORC2 activity. Upon activation, mTOR 
forms two multi-protein complexes, mTORC1 and mTORC2. 
P70 S6K is a well-defined substrate of mTORC1, and mTORC1 
activity can be determined by the phosphorylation status of 
p70 S6KThr389 or ribosomal subunit S6KSer235/236. mTORC2 
activity can be measured by assessing the phosphorylation of 
AKTSer473. To investigate whether the ATP-competitive binding 
site inhibitor PP242 is effective in inhibiting both complexes, 
we analyzed the phosphorylation statuses of p70 S6KThr389 and 
AKTSer473 after rapamycin or dose-dependent treatments with 
PP242 (2.2 or 1 µM) for 24h (Fig. 1). 
western blots were also stripped and re-probed for total 
p70 S6K or akt antibodies (Fig. 1a). Densitometric quantifica-
tion of p-p70 S6K/total p70 S6K (Thr389) and p-p85 S6K/total 
p85 S6K (Thr412) ratio demonstrated a significant decline in the 
phosphorylation of p70 S6K/p85 S6K, mTORC1 substrates, 
following treatment of GBM cells with either rapamycin 
or PP242 (1 or 2.2 µM) (Fig. 1B). PP242 demonstrated a 
dose-dependent suppression of p70 S6K phosphorylation, 
with PP242 yielding greater suppression of p70 S6K than 
rapamycin even at the lower dose (Fig. 1B, top panel). The 
lower dose of PP242 (1 µM) suppressed p85 S6K kinase 
more than the higher dose of PP242 (2.2 µM) and rapamycin 
(Fig. 1B, bottom panel). we also stimulated cells with either 
Insulin or TPA with or without pretreatment with rapamycin 
or PP242 (Fig. 1A). The densitometric analysis of p-p70 S6K/
p70 S6K (S70 and S85) demonstrated that the phosphorylation 
of p70 S6K was strongly increased by insulin or TPA treat-
ments, an effect markedly suppressed by pretreatment of GBM 
cells with either rapamycin or PP242 (Fig. 1B). This may imply 
that dose effect saturation was achieved as similar effects were 
seen even at the lower dose.
Treatment with mTORC1/2 inhibitor PP242 or rapamycin 
suppressed the activity of mTORC2 as shown by decreased 
phosphorylation of AKTSer473 in Fig. 1A. Densitometric quan-
tification of paKT/total aKT demonstrated a dose-dependent 
response (Fig. 1C). More specifically, PP242 at a lower 
concentration (1 µM) decreased the activation of pAKT by 
~40% while a higher dose (2.2 µM) reduced the expression of 
pAKT activation by ~80%. As a comparison, we studied the 
effect of rapamycin on activation of AKT and, densitometric 
quantification demonstrated that pretreatment with rapamycin 
also reduced expression of pAKT, albeit to a lesser extent than 
did treatment with PP242 (2.2 µM) (Fig. 1C). The GBM cells 
that were treated with rapamycin (100 nM) demonstrated a 
50% suppression in the levels of phosphorylated AKTSer473 
(Fig. 1C). Furthermore, insulin-induced activation of AKT, 
as seen by higher expression of pAKTSer473, was suppressed 
by pretreatment with rapamycin or PP242 at both doses 
(1 and 2.2 µM) (Fig. 1C). On the other hand, in this study we 
found that TPA was unable to activate AKT, as evidenced by 
unchanged pAKT levels with or without pretreatment with 
PP242 (Fig. 1A and C).
Effect of PP242 on ERK activation. Our previous findings 
have demonstrated that prolonged administration of rapamycin 
caused a progressive increase in activation of ERK as evident 
by increased levels in pERKThr202/Tyr204 (28). Fig. 2A presents 
western blot analysis of the effect of pretreatment with PP242 
(1 and 2.2 µM), in the presence or absence of TPA or insulin, 
on peRK expression (Fig. 2a). Densitometric quantification 
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Figure 1. The ATP-competitive binding site inhibitor PP242, suppresses both mTORC1 and mTORC2 activity, a comparison with rapamycin. (A) Immunoblotting 
analysis demonstrated that the aTP-competitive binding site inhibitor PP242 (1 or 2.2 µM) significantly suppressed the activation of p70 S6KThr389 and 
p85 S6KThr412, as demonstrated by reduced expression of both subunits of this kinase (70 and 85). The known inhibitor of mTORC1, rapamycin (100 nM), also 
suppressed activation of p70 S6KThr389 and p85 S6KThr412, albeit to a lesser extent than PP242 (1 or 2.2 µM). Insulin or TPA induced activation of p70 S6K was 
suppressed by pretreatment with PP242 (1 or 2.2 µM), and to a lesser extent by rapamycin (100 nM). Immunoblotting analysis showed PP242 caused significant 
inhibition in pAKTSer473 expression at higher dose (2.2 µM). Low dose PP242 (1 µM) suppressed pAKTSer473 expression similar to rapamycin (100 nM). Insulin 
increased pAKTSer473, which remained activated in rapamycin pretreated cells. Pretreatment with PP242 partially reversed insulin-induced activation of 
pAKTSer473. TPA failed to induce the expression of pAKTSer473, which remained unchanged following pretreatment with rapamycin (100 nM) or PP242 (1 or 
2.2 µM). GaPDH expression showed equal protein loading in all samples. (B) Densitometric quantification of p-p70 S6K/total p70 S6K ratio demonstrated a 
decline in p70 S6K activity. The effect was greatest with PP242 (2.2 µM), while PP242 (1 µM) or rapamycin (100 nM) rendered comparable results (top panel). 
Analysis of p-p85 S6K/total p85 S6K ratio demonstrated a decline in p85 S6K activity following treatment with PP242. The effect was greatest for lower 
dose PP242 (1 µM), while PP242 (2.2 µM) or rapamycin (100 nM) yielded comparable results (bottom panel). Analysis of p-p70 S6K/p70 S6K (S70 and S85) 
showed activation by insulin or TPa treatment was markedly suppressed by pretreatment with PP242. (C) Higher dose PP242 (2.2 µM) showed a significant 
decline in pAKTSer473 expression. A similar response of lesser magnitutude was observed for the lower dose PP242 (1 µM) or rapamycin (100 nM) Following 
pretreatment with higher dose, PP242 (2.2 µM) was able to partially reverse insulin-induced pAKTSer473 expression, while TPA had no effect on pAKTSer473 
expression in the presence, or absence, of rapamycin (100 nM) or PP242 (1 µM).
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shows that, at a lower dose of PP242, practically no activation 
of ERK was evident; however, a modest increase in expres-
sion of pERKThr202/Tyr204 (~20%) was seen following PP242 
(2.2 µM) treatment (Fig. 2B). In our study, Insulin treatment 
did not activate ERK, as shown by no difference in levels of 
pERKThr202/Tyr204, and further pretreatment of PP242 did not 
alter the levels of pERK in insulin treated cells (Fig. 2B). As 
expected, TPA induced robust activation of ERK; however, 
this activation was not suppressed by pretreatment with PP242 
(Fig. 2B). This implies that TPA induced activation of ERK 
was not intercepted by the inhibition of mTOR pathway.
Effect of PP242 and rapamycin on GBM cell proliferation, 
S-phase entry and migration. Quiescent cells were treated 
with rapamycin (100 nM) or PP242 (1 or 2.2 µM) for 24 h. 
Results show that GBM cell proliferation was suppressed by 
PP242 in a dose-dependent manner. Rapamycin (100 nM) was 
able to suppress cell viability in a manner similar to low dose 
PP242 (1 µM), while the high dose of PP242 (2.2 µM) was 
most effective in reducing cell proliferation (Fig. 3A).
S-phase entry analysis was performed using EdU incor-
poration following treatment with PP242, rapamycin, or 
PDGF (Fig. 3B). PP242, an inhibitor of mTORC1/2, caused a 
significant decrease in the number of cells entering S-phase. 
Similarly, rapamycin, which inhibits mTORC1 only, also 
showed a decrease in cells entering S-phase but to a lesser 
extent than PP242 (2.2 µM) (Fig. 3B). As expected, PDGF 
caused a significant number cells entering into S-phase as 
shown by an increase in the amount of EdU-incorporation, 
suggesting a robust increase in cell cycle, relative to vehicle 
treated controls (Fig. 3B).
Chemotactic migration was used to determine the effect 
of rapamycin and PP242 on GBM cell migration. As shown 
in (Fig. 3C), the cells were allowed to migrate toward fibro-
nectin, an extracellular matrix for 4 h. The migration of GBM 
cells was notably suppressed by pretreatment with PP242 
(2.2 µM). Rapamycin (100 nM) also significantly suppressed 
the migration of GBM cells. PP242 (2.2 µM) showed greater 
suppression of chemotactic migration than rapamycin. The 
effect of these compounds was evidently due to their effect 
on the cell signaling cascade regulation of cellular migration, 
since treatment with rapamycin or PP242 had no effect on 
cytoskeletal actin polymerization (Fig. 3D), as demonstrated 
by treated GBM cells stained with rhodamine palladine.
Discussion
The results of this study clearly demonstrated that a combined 
inhibitor of mTORC1/2 effectively suppressed both complexes 
and thereby inhibited cell proliferation as well as migration. 
PP242 treatment abolished the activation of mTORC1 substrate 
p70 S6K and mTORC2 substrate AKTSer473. This effect was 
stable since treatment with tumor promoting agent TPA failed 
to restore the activation of p70 S6K in PP242 treated cells. 
Similarly, in cells pretreated with PP242, TPA treatment 
remained ineffective at restoring pAKT expression. Moreover, 
we demonstrated that the rapamycin reduced the activation 
of mTORC2 substrate, although the effect was somewhat 
weaker. The analysis of cell proliferation and growth showed 
that PP242 was more effective than rapamycin in suppressing 
GBM cell proliferation as well as S-phase entry. GBM cell 
motility was suppressed more by PP242 than rapamycin.
we provided evidence that both mTORC1 and mTORC2 
complexes will need to be targeted in order to effectively 
block mTOR activity in GBM (30). Prolonged treatment 
with rapamycin may lead to activation of ERK pathway and 
mTORC2 complex, which promotes growth and cell motility 
in GBM cells (28,30,34). Administration of rapamycin caused 
an increased sensitivity to radiation of a U87 xenograft and 
significantly increased the re-growth delay of tumor, which 
was attributed to the rapamycin effect on decreased cell 
proliferation and cell cycle arrest (35). PP242 is an inhibitor 
of mTORC1 and mTORC2 as it completely inhibited the 
activation of p70 S6K, as well as AKT, while rapamycin 
only inhibits the mTORC1 complex (36). we observed both 
subunits of p70 S6K were dephosphorylated by PP242 treat-
ment. Downstream of mTORC1, the kinase S6K1 is a key 
regulator of protein synthesis linked with diverse mitogenic 
stimuli. p70 S6K exists in two distinct S6 kinases, p90 S6K 
and p70/85 S6K. The latter kinase consists of two isoforms, 
one 70-kD cytoplasmic isoform (p70 S6K) and the other 
nuclear (p85 S6K). Both isoforms appear to phosphorylate 
Figure 2. Effect of combined mTORC1/2 inhibitor, PP242 on the activation of 
MAP kinase. (A) Treatment with the combined mTORC1/2 inhibitor, PP242 
(1 or 2.2 µM), failed to alter the expression of pERK1/2 as compared to con-
trols. Levels of activated ERK1/2 remained unaffected following treatment 
with insulin (15 min) or insulin (15 min) given after pretreatment with PP242 
(1 or 2.2 µM) (24 h). Pretreatment with PP242 (1 or 2.2 µM) was ineffective 
in reducing TPA-induced expression of pERK1/2. (B) Densitometric analysis 
demonstrated the ratio of pERK1/2:tERK1/2 following PP242 (1 or 2.2 µM) 
treatment with or without concomitant insulin or TPA treatment.
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the S6 protein and mediate translation of polypyrimidine tract 
mRNA. Furthermore, studies have shown that the translational 
control of DNA synthesis, in particular the transition from G1 
to S-phase, is regulated by its nuclear localization.
The best-known substrates of mTORC1 are S6 kinase 
(S6K) and 4E-BP1 (eukaryotic initiation factor 4E-binding 
protein-1); the main substrates of TORC2 are AKT and related 
kinases (15). Rapamycin (sirolimus) and its analogs, such as 
RAD001 (everolimus) and CCI-779 (temsirolimus), suppress 
mTOR activity through an allosteric mechanism that acts at a 
distance from the ATP-catalytic binding site. Mechanistically, 
rapamycin has two main drawbacks. First, the drug suppresses 
mTORC1-mediated S6K activation, thereby blocking a nega-
tive feedback loop, but it does not inhibit mTORC2. In many 
cancer cells, this leads to elevated PI3K/AKT signaling, thereby 
promoting cell survival. Second, rapamycin is an incomplete 
inhibitor of mTORC1, reducing phosphorylation of 4E-BP1 
only partially in most cell contexts. mTOR pathway activa-
tion can be achieved through multiple pathways. Activating 
mutations of PI3K/mTOR are common in a majority of GBM 
patients, resulting in an increased phoshorylation of key 
signaling proteins in the PI3K pathway (37,38). Our results 
show that both subunits of p70 S6K were de-phosphorylated 
by treatment with PP242. PI3K and mTOR pathway in GBM 
can also be activated by amplification of eGFR due to the 
presence of an activating mutation, most commonly occurring 
at EGFRvIIII. In addition, c-MET and PDGFRα are other 
RTKs that also contribute to activation of the PI3K pathway.
Upon activation, mTOR forms two distinct multi-protein 
complexes, mTORC1 and mTORC2. mTORC1 displays 
sensitivity to rapalogues such as rapamycin, everolimus 
and temsirolimus, and mTORC2 is considered resistant to 
Figure 3. Effect of mTORC1/2 inhibitor on GBM cell proliferation, cell cycle entry, migration and cell dynamics. (A) The GBM cell proliferation was 
determined by MTT assay. GBM cell proliferation was suppressed in a dose-dependent manner by treatment with PP242 (2.2 µM and 1.1 µM). Rapamycin 
also suppressed cell viability. (B) Cell cycle analysis (left panel), demonstrating EDU incorporation, showed that PP242 (2.2 µM), more so than rapamycin 
(100 nM), significantly suppressed the number of cells entering S-phase, as compared to controls. Quantitative data (right panel) presented in stacked bar 
graphs showed that PDGF treatment significantly increased the number of edu positive cells, compared to controls (set to 100); PP242 (2.2 µM) and rapamycin 
(100 nM) demonstrated a reduction in S-Phase entry. (C) The chemotactic migration demonstrated that both PP242 (2.2 µM) and rapamycin (100 nM) sup-
pressed cell migration after 24 h of treatment; however, PP242 (2.2 µM) was more effective than rapamycin (100 nM). (D) F-actin analysis demonstrated that 
the F-actin expression of migrating cells was unaffected by rapamycin (100 nM) or PP242 (2.2 µM), suggesting no loss of cellular architecture. Rhodamine 
palladine was used to stain F-actin. (E) A schematic representation of two multiprotein complexes of mTOR, mTOR complex 1 (mTORC1) and mTOR complex 2 
(mTORC2), and inhibitors of rapamycin and PP242 inhibit mTORC1 and mTORC1/mTORC2, respectively. Indication of a ‘p' before any protein shows that 
the protein is phosphorylated/activated. RTK, receptor tyrosine kinase; PI3K, phosphoinositide 3-kinase; PIP2, phosphatidylinositol bisphosphate; PIP3, 
phosphatidylinositol (3,4,5)-trisphosphate; PTEN, phosphatase and tensin homolog; mTOR, mechanistic target of rapamycin; Raptor, rapamycin-sensitive 
adapter protein of mTOR; Rictor, rapamycin-insensitive companion of mTOR.
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rapamycin and insensitive to nutrient signals. The second 
subunit of the mTORC1 complex, mLST8, is considered to 
bind to the kinase domain of mTOR and to positively regulate 
its kinase activity. mLST8 is also important in maintaining the 
interaction between mTOR and either RAPTOR or RICTOR 
(Rapamycin-insensitive companion of mTOR), which is part 
of the mTORC2 complex and thus, thought to be important 
for shuttling mTOR between the two complexes as well as 
for sustaining the intracellular equilibrium of mTORC1 and 
mTORC2 (29,39,40).
we show herein that a selective, active-site mTOR kinase 
inhibitor has potent effects. Active-site inhibition of TORC1/2 
addresses rapamycin-resistant mTORC1 outputs and prevents 
activation of AKT resulting from feedback regulation (Fig. 1). 
mTORC1/2 inhibition caused selective growth suppression 
of which the likely mechanism is that the PI3K/AKT/mTOR 
pathway which is sustained by nutrients and growth factors. 
One possibility is that rapamycin alters a non-catalytic 
scaffolding-binding site of mTOR without affecting the active 
binding site. PP242, an ATP-competitive binding inhibitor 
of mTOR, is one of the new generations of mTOR inhibitors. 
Compared with rapamycin, PP242 more efficiently inhibits 
mTORC1, as evidenced by diminished p70 S6K phophoryla-
tion. Unlike rapamycin, PP242 nearly abolishes activation of 
AKT thus inhibiting the mTORC2. Rapamycin suppression of 
paKT was also not further influenced by treatment with TPa, 
implying that TPA has a limited effect on pAKT expression. 
Insulin was able to activate AKT, which was suppressed in 
part by pretreatment with rapamycin and PP242. 
Furthermore, the dose-dependent PP242-induced pAKT 
suppression was not observed following treament of GBM 
cells with insulin. Importantly TPA was unable to affect the 
activation of AKTSer473, suggesting that TPA does not affect 
the PI3K/AKT axis in these cells, and further pretreatment 
with PP242 or rapamycin remained ineffective. These findings 
suggest that PP242 was effective in suppressing mTORC1 and 
mTORC2 activity (Fig. 1).
Our results show that the ATP-competitive binding inhibitor 
PP242, unlike rapamycin, remained less effective in inducing 
ERK activation (Fig. 2) (28). Notably, prolonged exposure 
to allosteric mTOR inhibitor rapamycin caused activation of 
a mitogenic pathway due to alteration of signaling feedback 
loops (28). At the range of IC50 dose (2.2 µM) of PP242, GBM 
cell proliferation was strongly suppressed in vitro. PP242 is 
more effective in preventing the occurrence of negative feed-
back loops by enhancing its inhibitory effect on mTORC2. 
Therefore, PP242 is a more potent inhibitor of proliferation 
and migration of GBM cells. These results suggest that ATP 
kinase mTOR inhibitors may have far superior effects by 
virtue of their ability to fully inhibit rapamycin sensitive and 
insensitive complexes.
Whether mTORC1/2 specific inhibitors offer an advantage 
over pan-PI3K/mTORC1/2 pathway inhibitors is still not fully 
defined. However, several studies have provided evidence that 
PI3K/mTORC1/2 inhibitors (P103) have effectively suppressed 
downstream pathways in many cancers (41). However, 
whether pan-PI3K/mTORC1/2 inhibitors will provide an 
acceptable therapeutic window in GBM remains to be seen. 
PI3K has numerous roles in cell survival, differentiation, 
metabolism and migration, some of which are independent 
of AKT and mTOR. Findings of this study suggest that, 
whereas mTORC1/2 and mTORC1 inhibitors both affect 
proliferation and migration, the mTORC1/2 inhibitors cause 
greater suppression. Feedback loop regulation of PI3K/
mTOR signaling has a significant on impact therapeutic 
responses, in particular monotherapy groups. For example, 
activation of p70 S6K by mTORC1 causes feedback inhibi-
tion of IGF-1/insulin signaling by phosphorylating IRS-1 
(insulin receptor substrate 1), causing IRS-1 degradation, and 
leads to decreased PI3K signaling and reduced AKT T308 
phosphorylation. However, rapalogue-induced inhibition of 
mTORC1 consequently inhibits p70S6K phosphorylation, 
reciprocally activating negative feedback loops but relieves 
this feedback and induces AKT T308 re-phosphorylation, 
and thus increases mTORC2 activation (30,42-45). In addi-
tion, resistance to chemotherapy, and hypersensitivity to the 
mTORC1 inhibitor, rapamycin, in tumors with low expression 
of the tumor suppressor gene PTEN (reviewed in ref. 46), 
may be overcome by the use of the ATP-competitive binding 
inhibitor of mTORC1/2, PP242.
Results herein indicate that selective mTORC1/2 inhibi-
tion is an attractive alternative approach that provides better 
efficacy for suppressing GBM growth and invasion. Moreover, 
these findings provide support for further preclinical and 
clinical studies of selective active-site mTOR inhibitors in 
brain tumors.
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